18th May 2006 18:14
Deltex Medical Group PLC18 May 2006 Deltex Medical Group plc Results of clinical audit 18 May 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'), theAIM listed haemodynamic monitoring company, today announces the results of anaudit into the effectiveness of it CardioQ(TM) device which were presented todayat a meeting of surgeons and anaesthetists in Glasgow. The audit conducted at the Royal Alexandria Hospital in Paisley by Dr DavidAlcorn and colleagues involved 30 patients undergoing major colorectal surgery,and aimed to discover whether patients' lengths of stay in hospital aftersurgery was reduced if their fluid status was optimised during surgery. Theaudit found that those patients subject to haemodynamic optimisation using theCardioQ had a mean length of stay of 9.55 days compared to 12 days for thosepatients that had received a standardised anaesthetic. Dr David Alcorn, who has been in charge of auditing the procedure at the RoyalAlexandra Hospital, said: "We are greatly encouraged by the results achieved. This has major benefits notonly for patients but for clinicians and hospitals throughout the country." Professor Monty Mythen of the Improving Surgical Outcomes Group commented: "This is just the sort of technique that we are trying to encourage hospitalsacross the UK to adopt. "Patients leave hospital faster after surgery, freeing up vital bed space. Therisk of complications is reduced and patients recover more quickly. "Around one million patients treated by the NHS could benefit from thisprocedure every year. Taking the cost of an average hospital bed at £500 perday, there are clearly significant financial savings possible. When savingsfrom not having to manage surgical complications are included, the impact couldbe immense." Deltex Medical's Chief Executive, Andy Hill, commented: "The evidence from this audit comprises further validation of the clinical andcost effectiveness of the CardioQ. This is the first such evidence to originatefrom Scotland and will help us to establish that the CardioQ should be standardclinical practice for patients undergoing moderate and major surgery." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman [email protected] Hill, Chief Executive [email protected] Phillips, Finance Director [email protected] Financial Dynamics 0207 831 3113David Yates [email protected] Gilbert [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amountof circulating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical